Luca Issi
Stock Analyst at RBC Capital
(0.95)
# 3,435
Out of 4,670 analysts
163
Total ratings
24.44%
Success rate
-19.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLUE bluebird bio | Reiterates: Sector Perform | $4 | $0.35 | +1,042.53% | 5 | Nov 15, 2024 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $9 → $11 | $5.93 | +85.50% | 5 | Nov 14, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $40 → $39 | $7.79 | +400.64% | 6 | Nov 14, 2024 | |
| QURE uniQure | Maintains: Outperform | $16 → $14 | $5.78 | +142.21% | 4 | Nov 6, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Outperform | $77 | $47.24 | +63.00% | 3 | Nov 6, 2024 | |
| VERV Verve Therapeutics | Maintains: Outperform | $20 → $17 | $4.85 | +250.52% | 6 | Nov 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Sector Perform | $53 | $47.88 | +10.69% | 12 | Nov 6, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $25 → $24 | $30.77 | -22.00% | 2 | Nov 6, 2024 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $27 → $24 | $25.05 | -4.19% | 6 | Nov 6, 2024 | |
| EDIT Editas Medicine | Maintains: Sector Perform | $8 → $5 | $2.44 | +104.92% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $10 | $6.04 | +65.56% | 6 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $244.89 | +22.50% | 23 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $64.26 | +24.49% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $14.27 | +5.12% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $105 | $52.31 | +100.73% | 6 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $34.01 | +105.82% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $18.54 | +126.54% | 7 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $75 | $41.11 | +82.44% | 12 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $14.30 | +277.62% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $6.47 | +270.94% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.02 | +593.07% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.21 | +352.49% | 7 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $1.88 | +6.38% | 5 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $20 → $35 | $9.59 | +264.96% | 7 | Mar 8, 2024 |
bluebird bio
Nov 15, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $0.35
Upside: +1,042.53%
MeiraGTx Holdings
Nov 14, 2024
Maintains: Outperform
Price Target: $9 → $11
Current: $5.93
Upside: +85.50%
4D Molecular Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $40 → $39
Current: $7.79
Upside: +400.64%
uniQure
Nov 6, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $5.78
Upside: +142.21%
Ultragenyx Pharmaceutical
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $47.24
Upside: +63.00%
Verve Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $20 → $17
Current: $4.85
Upside: +250.52%
CRISPR Therapeutics AG
Nov 6, 2024
Reiterates: Sector Perform
Price Target: $53
Current: $47.88
Upside: +10.69%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Sector Perform
Price Target: $25 → $24
Current: $30.77
Upside: -22.00%
Beam Therapeutics
Nov 6, 2024
Maintains: Sector Perform
Price Target: $27 → $24
Current: $25.05
Upside: -4.19%
Editas Medicine
Nov 5, 2024
Maintains: Sector Perform
Price Target: $8 → $5
Current: $2.44
Upside: +104.92%
Nov 5, 2024
Maintains: Sector Perform
Price Target: $12 → $10
Current: $6.04
Upside: +65.56%
Nov 1, 2024
Reiterates: Outperform
Price Target: $300
Current: $244.89
Upside: +22.50%
Oct 30, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $64.26
Upside: +24.49%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $14.27
Upside: +5.12%
Oct 21, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $52.31
Upside: +100.73%
Sep 26, 2024
Reiterates: Outperform
Price Target: $70
Current: $34.01
Upside: +105.82%
Sep 26, 2024
Reiterates: Outperform
Price Target: $42
Current: $18.54
Upside: +126.54%
Sep 19, 2024
Reiterates: Sector Perform
Price Target: $75
Current: $41.11
Upside: +82.44%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $14.30
Upside: +277.62%
Aug 13, 2024
Reiterates: Outperform
Price Target: $24
Current: $6.47
Upside: +270.94%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.02
Upside: +593.07%
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.21
Upside: +352.49%
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $1.88
Upside: +6.38%
Mar 8, 2024
Upgrades: Outperform
Price Target: $20 → $35
Current: $9.59
Upside: +264.96%